Do rich markets lure biotechs away from low-cost remedies?


A pair of Canadian researchers has taken a close look at 78 small biotech companies operating in India, Brazil, China and South Africa and found that many are pursuing a host of new drugs and vaccines that would be affordable in the developing world. But there's a caveat: Many of these developers may be deflected from their mission if they're hijacked by companies more interested in treating the diseases that afflict the affluent in industrial countries. Article

Filed Under